Synthaverse S.A. (SVE.WA)
PLN 4.28
(7.0%)
PLN 4.28
(7.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 153.26 Million PLN | 166.37% |
| 2022 | 57.53 Million PLN | 36.11% |
| 2021 | 42.27 Million PLN | -12.94% |
| 2020 | 48.55 Million PLN | 0.65% |
| 2019 | 48.24 Million PLN | -13.63% |
| 2018 | 55.85 Million PLN | -11.65% |
| 2017 | 63.21 Million PLN | -43.32% |
| 2016 | 111.53 Million PLN | -23.69% |
| 2015 | 146.15 Million PLN | 165.36% |
| 2014 | 55.08 Million PLN | 40.44% |
| 2013 | 39.22 Million PLN | -20.57% |
| 2012 | 49.37 Million PLN | -12.13% |
| 2011 | 56.19 Million PLN | -5.41% |
| 2010 | 59.4 Million PLN | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 179.47 Million PLN | 17.1% |
| 2024 Q2 | 179.58 Million PLN | 0.06% |
| 2023 Q2 | 84.32 Million PLN | 25.31% |
| 2023 Q4 | 153.26 Million PLN | 28.03% |
| 2023 FY | 153.26 Million PLN | 166.37% |
| 2023 Q3 | 119.7 Million PLN | 41.96% |
| 2023 Q1 | 67.29 Million PLN | 16.96% |
| 2022 Q3 | 49.27 Million PLN | 6.52% |
| 2022 FY | 57.53 Million PLN | 36.11% |
| 2022 Q2 | 46.25 Million PLN | -3.48% |
| 2022 Q4 | 57.53 Million PLN | 16.78% |
| 2022 Q1 | 47.92 Million PLN | 13.37% |
| 2021 Q3 | 45.01 Million PLN | 0.0% |
| 2021 Q4 | 42.27 Million PLN | -6.09% |
| 2021 FY | 42.27 Million PLN | -12.94% |
| 2021 Q1 | 48.92 Million PLN | 0.77% |
| 2020 Q2 | 47.91 Million PLN | 8.75% |
| 2020 Q4 | 48.55 Million PLN | 2.96% |
| 2020 FY | 48.55 Million PLN | 0.65% |
| 2020 Q3 | 47.15 Million PLN | -1.58% |
| 2020 Q1 | 44.06 Million PLN | -8.67% |
| 2019 Q3 | 52.03 Million PLN | -7.48% |
| 2019 Q4 | 48.24 Million PLN | -7.29% |
| 2019 Q2 | 56.24 Million PLN | -0.02% |
| 2019 Q1 | 56.25 Million PLN | 0.71% |
| 2019 FY | 48.24 Million PLN | -13.63% |
| 2018 Q3 | 54.09 Million PLN | -10.19% |
| 2018 Q1 | 59.25 Million PLN | -6.27% |
| 2018 Q4 | 55.85 Million PLN | 3.25% |
| 2018 FY | 55.85 Million PLN | -11.65% |
| 2018 Q2 | 60.23 Million PLN | 1.66% |
| 2017 Q4 | 63.21 Million PLN | -35.26% |
| 2017 FY | 63.21 Million PLN | -43.32% |
| 2017 Q2 | 102.54 Million PLN | -1.91% |
| 2017 Q3 | 97.64 Million PLN | -4.78% |
| 2017 Q1 | 104.54 Million PLN | -6.26% |
| 2016 Q4 | 111.53 Million PLN | -12.96% |
| 2016 FY | 111.53 Million PLN | -23.69% |
| 2016 Q2 | 128.77 Million PLN | -9.78% |
| 2016 Q3 | 128.13 Million PLN | -0.49% |
| 2016 Q1 | 142.72 Million PLN | -2.35% |
| 2015 Q4 | 146.15 Million PLN | 39.96% |
| 2015 FY | 146.15 Million PLN | 165.36% |
| 2015 Q3 | 104.43 Million PLN | 10.07% |
| 2015 Q2 | 94.87 Million PLN | 25.94% |
| 2015 Q1 | 75.33 Million PLN | 36.77% |
| 2014 FY | 55.08 Million PLN | 40.44% |
| 2014 Q1 | 42.06 Million PLN | 7.26% |
| 2014 Q2 | 53.9 Million PLN | 28.15% |
| 2014 Q4 | 55.08 Million PLN | -18.95% |
| 2014 Q3 | 67.95 Million PLN | 26.05% |
| 2013 Q3 | 51.18 Million PLN | 2.73% |
| 2013 Q4 | 39.22 Million PLN | -23.38% |
| 2013 Q2 | 49.82 Million PLN | -0.42% |
| 2013 Q1 | 50.03 Million PLN | 1.34% |
| 2013 FY | 39.22 Million PLN | -20.57% |
| 2012 Q4 | 49.37 Million PLN | 0.0% |
| 2012 FY | 49.37 Million PLN | -12.13% |
| 2011 FY | 56.19 Million PLN | -5.41% |
| 2010 FY | 59.4 Million PLN | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioceltix S.A. | 2.26 Million PLN | -6655.953% |
| BIOTON S.A. | 215.86 Million PLN | 29.0% |
| Captor Therapeutics Spolka Akcyjna | 28.07 Million PLN | -445.929% |
| Mabion S.A. | 90.47 Million PLN | -69.394% |
| Molecure S.A. | 11.34 Million PLN | -1250.975% |
| NanoGroup S.A. | 1.49 Million PLN | -10185.505% |
| Pharmena S.A. | 1.9 Million PLN | -7941.133% |
| Poltreg S.A. | 39.58 Million PLN | -287.216% |
| Pure Biologics Spólka Akcyjna | 20.84 Million PLN | -635.255% |
| Ryvu Therapeutics S.A. | 120.36 Million PLN | -27.338% |
| Urteste S.A. | 1.85 Million PLN | -8162.21% |